Table Of ContentAntibody Expression and Production
Cell Engineering
Volume7
SeriesEditor
ProfessorMohamedAl-Rubeai
UCDSchoolofChemicalandBioprocessEngineering
UniversityCollegeDublin
Dublin,Ireland
EditorialBoard
DrHansjorgHauser
HelmholtzCentreforInfectionResearch
Braunschweig
Germany
ProfessorMichaelBetenbaugh
JohnsHopkinsUniversity
Baltimore,USA
ProfessorMartinFussenegger
SwissFederalInstituteofTechnology
Zurich,Switzerland
ProfessorNigelJenkins
NationalInstituteforBioprocessingResearchandTraining
Dublin,Ireland
DrOtto-WilhelmMerten
A.F.M.-Genethon11
GeneTherapyProgram
Evry,France
Forothertitlespublishedinthisseries,goto
http://www.springer.com/series/5728
CELL ENGINEERING
Vol. 7: Antibody Expression
and Production
Editedby
MohamedAl-Rubeai
UniversityCollegeDublin,Ireland
123
Editor
Prof.MohamedAl-Rubeai
SchoolofChemicalandBioprocess
Engineering
UniversityCollegeDublin
Dublin
Ireland
[email protected]
ISSN1389-6946
ISBN978-94-007-1256-0 e-ISBN978-94-007-1257-7
DOI10.1007/978-94-007-1257-7
SpringerDordrechtHeidelbergLondonNewYork
LibraryofCongressControlNumber:2011928367
©SpringerScience+BusinessMediaB.V.2011
Nopartofthisworkmaybereproduced,storedinaretrievalsystem,ortransmittedinanyformorby
anymeans,electronic,mechanical,photocopying,microfilming,recordingorotherwise,withoutwritten
permissionfromthePublisher,withtheexceptionofanymaterialsuppliedspecificallyforthepurpose
ofbeingenteredandexecutedonacomputersystem,forexclusiveusebythepurchaserofthework.
Printedonacid-freepaper
SpringerispartofSpringerScience+BusinessMedia(www.springer.com)
Contents
1 ExpressionofAntibodyinMammalianCells. . . . . . . . . . . . . 1
ThomasJostock
2 Bioreactor Systems for Producing Antibody from
MammalianCells . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
DarrinKuystermansandMohamedAl-Rubeai
3 ProductionofAntibodyinInsectCells . . . . . . . . . . . . . . . . 53
HidekiYamaji
4 ProductionofMonoclonalAntibodiesinGlycoengineered
Pichiapastoris . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
DongxingZha,ThomasLinden,andThomasPotgieter
5 ProductionofAntibodiesinHansenulapolymorpha . . . . . . . . . 99
GeorgMelmer,StephanHellwig,GritHehmann,andUlrikeDahlems
6 ProductionofAntibodybyTransgenicAvians . . . . . . . . . . . . 121
YoshinoriKawabeandMasamichiKamihira
7 ProductionofAntibodiesinPlants . . . . . . . . . . . . . . . . . . 143
AlejandroSarrion-Perdigones,PalomaJuarez,
AntonioGranell,andDiegoOrzaez
8 Production of Antibody Fab Fragments
inEscherichiacoli . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
HiroshiTachibanaandMasatakaTakekoshi
9 IntrabodyExpressioninMammalianCells. . . . . . . . . . . . . . 179
SilviaBiocca
10 EngineeringAntibodiesforCancerTherapy . . . . . . . . . . . . . 197
LisaE.GoldsmithandMatthewK.Robinson
11 Recombinant Bispecific Antibodies
forCancerTherapy . . . . . . . . . . . . . . . . . . . . . . . . . . 235
DafneMüllerandRolandE.Kontermann
v
vi Contents
12 TheRoleofGlycosylationinTherapeuticAntibodies . . . . . . . . 251
MaureenSpearman,BenDionne,andMichaelButler
13 QualityIssuesArisingfromPost-translationalModification
ofRecombinantAntibodies . . . . . . . . . . . . . . . . . . . . . . 293
RaymondTytherandNigelJenkins
14 RecoveryandPurificationofAntibody . . . . . . . . . . . . . . . . 305
XueJunHan,ArthurHewig,andGaneshVedantham
SubjectIndex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 341
Contributors
MohamedAl-Rubeai SchoolofChemicalandBioprocessEngineering,and
ConwayInstituteofBiomolecularandBiomedicalResearch,UniversityCollege
Dublin,Dublin,Ireland,[email protected]
SilviaBiocca DepartmentofNeuroscience,UniversityofRome“TorVergata”,
00133Rome,Italy,[email protected]
MichaelButler DepartmentofMicrobiology,UniversityofManitoba,Winnipeg,
MB,CanadaR3T2N2,[email protected]
UlrikeDahlems PharmedArtisGmbH,Forckenbeckstr.6,D-52074Aachen,
Germany,[email protected]
BenDionne DepartmentofMicrobiology,UniversityofManitoba,Winnipeg,
MB,CanadaR3T2N2,[email protected]
LisaE.Goldsmith DevelopmentalTherapeuticsProgram,FoxChaseCancer
Center,Philadelphia,PA19111,USA,[email protected]
AntonioGranell InstitutodeBiologíaMolecularyCelulardePlantas(IBMCP),
UPV-CSIC,46022Valencia,Spain,[email protected]
XueJunHan AmgenInc.,Seattle,WA98119,USA,[email protected]
GritHehmann PharmedArtisGmbH,Forckenbeckstr.6,D-52074Aachen,
Germany,[email protected]
StephanHellwig PharmedArtisGmbH,Forckenbeckstr.6,D-52074Aachen,
Germany,[email protected]
ArthurHewig AmgenInc.,Seattle,WA98119,USA,[email protected]
NigelJenkins NationalInstituteforBioprocessingReasearchandTraining,
UniversityCollegeDublin,Dublin,Ireland,[email protected]
ThomasJostock NovartisPharmaAG,CH-4002Basel,Switzerland,
[email protected]
PalomaJuarez InstitutodeBiologíaMolecularyCelulardePlantas(IBMCP),
UPV-CSIC,46022Valencia,Spain,[email protected]
vii
viii Contributors
MasamichiKamihira DepartmentofChemicalEngineering,Facultyof
Engineering,KyushuUniversity,Fukuoka819-0395,Japan,
[email protected]
YoshinoriKawabe DepartmentofChemicalEngineering,Facultyof
Engineering,KyushuUniversity,Fukuoka819-0395,Japan,
[email protected]
RolandE.Kontermann InstitutfürZellbiologieundImmunologie,Universität
Stuttgart,70569Stuttgart,Germany,[email protected]
DarrinKuystermans SchoolofChemicalandBioprocessEngineering,and
ConwayInstituteofBiomolecularandBiomedicalResearch,UniversityCollege
Dublin,Dublin,Ireland,[email protected]
ThomasLinden BioprocessDevelopment,Merck&Co,Rahway,NJ07065,
USA,[email protected]
GeorgMelmer PharmedArtisGmbH,Forckenbeckstr.6,D-52074Aachen,
Germany,[email protected]
DafneMüller InstitutfürZellbiologieundImmunologie,UniversitätStuttgart,
70569Stuttgart,Germany,[email protected]
DiegoOrzaez InstitutodeBiologíaMolecularyCelulardePlantas(IBMCP),
UPV-CSIC,46022Valencia,Spain,[email protected]
ThomasPotgieter BioprocessDevelopment,Merck&Co,Rahway,NJ07065,
USA,[email protected]
MatthewK.Robinson DevelopmentalTherapeuticsProgram,FoxChaseCancer
Center,Philadelphia,PA19111,USA,[email protected]
AlejandroSarrion-Perdigones InstitutodeBiologíaMolecularyCelularde
Plantas(IBMCP),UPV-CSIC,46022Valencia,Spain,[email protected]
MaureenSpearman DepartmentofMicrobiology,UniversityofManitoba,
Winnipeg,MB,CanadaR3T2N2,[email protected]
HiroshiTachibana DepartmentofInfectiousDiseases,TokaiUniversitySchool
ofMedicine,Isehara,Kanagawa259-1193,Japan,[email protected]
MasatakaTakekoshi DepartmentofMolecularLifeScience,TokaiUniversity
SchoolofMedicine,Isehara,Kanagawa259-1193,Japan,
[email protected]
RaymondTyther NationalInstituteforBioprocessingReasearchandTraining,
UniversityCollegeDublin,Dublin,Ireland,[email protected]
GaneshVedantham AmgenInc.,Seattle,WA98119,USA,
[email protected]
Contributors ix
HidekiYamaji DepartmentofChemicalScienceandEngineering,Graduate
SchoolofEngineering,KobeUniversity,Kobe657-8501,Japan,
[email protected]
DongxingZha GlycoFiInc.(Awholly-ownedsubsidiaryofMerck&CoInc.),
Lebanon,NH03766,USA,[email protected]
Description:Engineered antibodies currently represent over 30% of biopharmaceuticals in clinical trials and their total worldwide sales continue to increase significantly. The importance of antibody applications is reflected in their increasing clinical and industrial applications as well as in the progression